These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

451 related items for PubMed ID: 3261626

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Importance of Lyt 2+ T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor.
    Mokyr MB, Barker E, Weiskirch LM, Takesue BY, Pyle JM.
    Cancer Res; 1989 Aug 15; 49(16):4597-606. PubMed ID: 2568174
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Importance of TNF production for the curative effectiveness of low dose melphalan therapy for mice bearing a large MOPC-315 tumor.
    Gorelik L, Rubin M, Prokhorova A, Mokyr MB.
    J Immunol; 1995 Apr 15; 154(8):3941-51. PubMed ID: 7706732
    [Abstract] [Full Text] [Related]

  • 10. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
    Mokyr MB, Ye QW.
    Cancer Res; 1985 Oct 15; 45(10):4932-9. PubMed ID: 4027979
    [Abstract] [Full Text] [Related]

  • 11. Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor.
    Mokyr MB, Kalinichenko TV, Gorelik L, Bluestone JA.
    J Immunol; 1998 Feb 15; 160(4):1866-74. PubMed ID: 9469448
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Insight into the mechanism of TCR-V beta 8+/CD8+ T cell-mediated MOPC-315 tumor eradication.
    Mokyr MB, Prokhorova A, Rubin M, Bluestone JA.
    J Immunol; 1994 Oct 01; 153(7):3123-34. PubMed ID: 8089490
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
    Ward BA, Shu S, Chou T, Perry-Lalley D, Chang AE.
    J Immunol; 1988 Aug 01; 141(3):1047-53. PubMed ID: 3260908
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.